AbCellera Biologics Inc.
ABCL
NASDAQ·Healthcare·Biotechnology·Mkt cap $3.5B
$11.43
▼ -1.21%
P/E
-21.17
Mkt Cap
$3.5B
52-Wk Range
$2.75–$12.58
52-Week Range
$2.75 - $12.58
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 174.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI-powered antibody discovery platform with proven track record
- Exclusive access to diverse natural immune system database and analytical capabilities
- Established partnerships with major pharmaceutical companies including Eli Lilly
- First-mover advantage in commercial AI-driven antibody discovery space
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Expansion of discovery partnerships and contracted programs with pharmaceutical companies
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Hot
+110.9% over 3m
Quality
Excellent
High-growth business (101% revenue growth, 75% gross margin). Pre-profit but investing in growth.
Dividend
None
No dividend
Smart-money signal
Who's buying ABCL right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 5, 2026
Reported EPS of -$0.18 vs -$0.14 consensus (-24.8% surprise). Revenue of $4.0M vs $7.8M expected (-48.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-24.8%
Revenue trend · last 8Q
—
—
-57%
+133%
+38%
+788%
+96%
-76%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$6.5M
$5.0M
$4.2M
$17.1M
$9.0M
$44.9M
$8.3M
$4.0M
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
-1368.6%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Benchmark · Jul 7, 2026
vs Industry
How ABCL stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related